Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers
Research type
Research Study
Full title
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers
IRAS ID
1006068
Contact name
Vicki Horton
Contact email
Sponsor organisation
Shattuck Labs, Inc.
Eudract number
2022-000698-17
Clinicaltrials.gov Identifier
Research summary
This research study will test the safety and find the best dose of SL-172154, the study drug, that can be given in combination with mirvetuximab soravtansine (MIRV), another drug that is under study by a different company, or Pegylated liposomal doxorubicin (PLD) to participants with ovarian cancer or a related cancer for which there are no standard therapies available. SL-172154 is an immunotherapy drug. Immunotherapies are treatments that use your body’s own immune (defense) system to help fight cancer. \n\nMIRV is designed to selectively kill tumours. The antibody (protein) part of MIRV targets tumours by delivering a cell-killing drug to the tumour cells. Researchers hope MIRV will cause the cancer cells to stop growing and spreading.\n\nPLD is a medication that blocks cell division and growth; this blocking action may kill cancer cells. PLD is an approved medicine used for the treatment of adults with ovarian cancer whose disease has gotten worse or recurred after a platinum-based chemotherapy.\n\nThis is an open label study with two parts: dose escalation and dose expansion. Your study doctor will let you know which part you will be enrolled into and whether you will receive PLD or MIRV along with SL-172154. Dose escalation will determine the dose of SL-172154 expected to be safe and tolerable in combination with PLD or MIRV. Dose expansion will start once the dose escalation part is completed and the safe and tolerable dose of each of the SL-172154 combination treatments is established.\n\nThe Sponsor of the study is Shattuck Labs, Inc. (Shattuck Labs). This study will include approximately 102 participants in total, from the USA, UK, Canada, and Spain.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
22/SC/0364
Date of REC Opinion
17 Nov 2022
REC opinion
Further Information Favourable Opinion